Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Investigation of Autophagy Markers in Endometrial Polyps

ID
Name
03.09.20-08/01
Description
The aim of this research is to evaluate autophagy markers in patients with endometrial polyps
Trial arms
Trial start
2021-01-08
Estimated PCD
2022-01-08
Trial end
2022-02-01
Status
Completed
Treatment
Beclin 1 gene
The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
Arms:
Control group, Study group
Other names:
LC3-II gene, p62 gene
Size
30
Primary endpoint
autophagy marker
through study completion, an average of 1 year
autophagy marker
through study completion, an average of 1 year
autophagy marker
through study completion, an average of 1 year
Eligibility criteria
Inclusion Criteria: * Patients over 35 years of age with a histopathologically confirmed diagnosis of endometrial polyp * patients over the age of 35 whose histopathologically reported normal endometrial biopsy results. Exclusion Criteria: * Are under the age of 35, * those with cognitive dysfunction, * diagnosed with any type of cancer * who are under treatment for cancer, * diabetes mellitus, * hypertension, * endometriosis, * adenomyosis, * chronic endometritis, * have an acute or chronic illness, * patients who have smoked and used alcohol in the last 10 years
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 30, 'type': 'ACTUAL'}}
Updated at
2023-12-06

1 organization

1 product

2 indications

Organization
Muğla Sıtkı Koçman University
Product
Beclin 1
Indication
Endometrial Polyp
Indication
Autophagy